Bacteria and viruses often use the normal biological properties of host adhesion molecules to infect relevant host cells. The outer membrane bacterial protein invasin mediates the attachment of Yersinia pseudotuberculosis to human cells. In vitro studies have shown that four members of the very late antigen (VLA) integrin family of adhesion molecules, VLA-3, VLA-4, VLA-5, and VLA-6, can bind to invasin. Since CD4 + T cells express and use these integrins, we have investigated the interaction of CD4 + T ceils with purified invasin. Although VLA integrinmediated adhesion of T cells to other ligands such as fibronectin does not occur at high levels unless the T cells are activated, resting T cells bind strongly to purified invasin. The binding of resting T ceUs to invasin requires metabolic activity and an intact cytoskdeton. Although CD4 + T cells express VLA-3, VLA-4, VLA-5, and VLA-6, monoclonal antibody (mAb) blocking studies implicate only VLA-4 as a T call invasin receptor. Like other integrin ligands, invasin can facilitate T call proliferative responses induced by a CD3-specific mAb. These results suggest that the nature of the integrin llgand is a critical additional factor that regulates T cell integrin activity, and that direct interactions of T cells with bacterial pathogens such as Yersinia may be relevant to host immune responses to bacterial infection.
T
he immune response is dependent on the physical interaction of its various cellular members with each other and with the surrounding microenvironment (1) . Integrins are a large family of c~//3 heterodimeric proteins that mediate the adhesion of many different cell types to other cells and to components of the extracellular matrix (ECM) such as fibronectin (FN), laminin, and collagen (1) (2) (3) . Since T cells must be able to rapidly alternate between adhesive and nonadhesive states, the functional activity ofintegrins expressed on T ceils is tightly regulated. T cell activation rapidly modulates the functional activity of four intega'ins expressed on peripheral T ceUs: the/32 integrin LFA-1 and the B1 integrins very late antigen (VLA)-4 (abo designated cx4/31), VLA-5 (oeSB1), and VLA-6 (o~6/31). Whereas resting T cells demonstrate minimal integrin-mediated adhesion, activation results within minutes in strong T cell adhesion to integrin ligands without a change in the level of cell surface expression of the integrin receptors themsdves (4) (5) (6) . Multiple activation signals can induce this rapid change in integrin activity, including treatment with the phorbol ester PMA, the Ca 2+ ionophore A23187, mitogenic pairs of CD2-specific mAbs, mAb cross-linking of the CD3-TCR complex, or mAb crosslinking of the T cell surface molecules CD7, CD28, or CD31 (4) (5) (6) (7) (8) . To date, this dependence on activation for strong T cell integrin function has been demonstrated for all of the integrin ligands tested, including the LFA-1 ligand intercellular adhesion molecule I (ICAM-1), the VLA-4 cell surface ligand vascular cell adhesion molecule (VCAM)-I, the VLA-4 and VLA-5 ligand FN, and the VLA-6 ligand laminin (4) (5) (6) (7) 9) .
Whereas adhesion molecules play a fundamentally critical role in immune system function, their adhesive properties are often used by bacteria and viruses as a means of entry and survival in the host organism (10, 11) . Recent studies of the intracellular bacterial pathogen Yersinia pseudotuberculosis have shown that the bacterial outer membrane protein invasin mediates the attachment and internalization of Yersinia by normally nonphagocytic cells by binding to four different VLA integrins: VLA-3, VLA-4, VLA-5, and VLA-6 (12, 13) . Since CD4 + T ceils express all of these VLA integrins (6) , and VLA-4 in particular is expressed predominantly by lymphoid cells (2), we hypothesized that the interaction of T cells with invasin may be critical to our understanding of integrin function and immune responses to this bacterial pathogen. We show in this study that: (a) strong T call binding to invasin occurs without activation, unlike binding to all other T cell integrin ligands tested to date; (b) the predominant invasin receptor on CD4 + T cells is VLA-4; and (c) invasin can facilitate CD3-mediated T cell proliferative responses.
Materiah and Methods
Human T Cells. Peripheral CD4 + T cells were isolated by negative magnetic immunosdection from either leukapheresis packs or buffy coats as previously described (6, 7, 14) . The T cell populations were typically >96% CD3+CD4 + as assessed by flow cytometric analysis. Complete depletion of monocytes in the T cell preparation was determined by the lack of proliferative response to optimal concentrations (1:200 dilution) of PHA (M form) (Gibco-BRL, Grand Ishnd, NY).
Antibodies and Other Reagents. The invasin utilized in this study is a fusion protein consisting of the COOH-terminal end of invasin (479 amino acids in length) and maltose binding protein (MBP) (13) . MBP and collagen (Sigma Chemical Co., St. Louis, MO) were used as negative control proteins. FN was purchased from the New York Blood Center (New York, NY). Cytochalasin B was purchased from Sigma Chemical Co., and stanrosporin was purchased from Boehringer Mannheim Diagnostics (Indianapolis, IN). Both were dissolved in DMSO before use. Dibutyryl cAMP (Calbiochem-Behring Corp., San Diego, CA) was dissolved in PBS before use.
Adhesion Assays. Adhesion assays were performed as described (6, 7) . Each well contained 50,000 SlCr-labded T ceils in a final volume of 0.1 ml PBS/0.5% HSA. For PMA activation, cells were added to wells containing 10 ng/ml PMA (Sigma Chemical Co.). All data are expressed as the mean percent of ceUs binding from three replicate wells plus SEM. In all mAb blocking experiments, mAbs were added to wells at 10/~g/ml (for purified IgG), 1:500 dilution (for ascites fluid) or 1:5 dilution (for culture supematants). Inhibitors were present throughout the assay at the concentrations indicated.
T Cell Proliferation Assays. Proliferation assays were performed essentially as previously described (19) . During the last 18 h of the assay, the culture was pulsed with 1 #Ci/well of pH]thymidine (New England Nuclear/Dupont, sp act of 6.7 Ci/mmol). Results are expressed as the arithmetic mean cpm of triplicate cultures. Microtiter plates (Costar Corp., Cambridge, MA) were prepared by first incubating indicated concentrations of the CD3 mAb OKT3 overnight at 4"C in PBS, washing away the unbound mAb, and adding the indicated concentrations of invasin or FN (diluted in PBS with Ca 2 § and Mg 2+) for an addition 2-3 h incubation at room temperature. Plates were washed three times with PBS before the start of culture, mAbs were added at the same concentrations used in the adhesion assays, except for culture supernatants, which were used at a 1:8 final dilution.
Results

Binding of Resting As Well As Activated T Cells To Purified
Invasion. Previous studies have shown that strong adhesion of human CD4 + T cells to relevant VLA ligands such as FN (via VLA-4 and VLA-5), laminin (via VLA-6), and VCAM-1 (via VLA-4) requires activation of the T cell by a stimulus such as PMA (6, 7, 9) . In contrast to the results obtained with these previously described VLA integrin ligands, resting CD4 + T ceUs bound strongly and in a dose-dependent fashion to purified invasin (Fig. 1) . Treatment of T cells for 10 min with 10 ng/ml PMA dramatically increased adhesion to FN, but only slightly increased adhesion to invasin (Fig.  1 ). An increase in binding to invasin after PMA activation of T cells was most evident at low doses of immobilized invasin. Similar results were obtained after activation ofT cells with other stimuli that increase VLA integrin-mediated binding to FN (6, 7 , and data not shown). of the erythroleukemia cell line K562 to invasin (12) , can also completely inhibit T cell adhesion to invasin. In addition, two other VLA/3 chain-specific mAbs, LIAI/2 and MAB13, can inhibit T cell adhesion to invasin. Three other VLA/3 chain-specific mAbs only partially inhibit T cell adhesion to invasin, suggesting that these mAbs recognize epitopes on the VLA/3 chain that are minimally involved in binding to invasin. Studies with various VLA c~ chain-specific mAbs demonstrate that one VLA-4 tx chain-specific mAb, HP1/2, can inhibit T cell adhesion to invasin as effectively as the inhibitory VLA/3 chain-specific mAbs (Fig. 2) . A panel of VLA-5 a chain-specific mAbs, all of which inhibit cell adhesion to FN, did not inhibit T cell adhesion to invasin. This panel includes one VLA-5-specific mAb (BIIG2) that was previously shown to inhibit the binding of K562 cells to invasin (12) . In addition, the VLA-3 oe chain-specific mAb PLB5 and the VLA-6 c~ chain-specific mAb GoH-3, both of which are functionally inhibitory mAbs (6, 20 , and Y. Shimizu, unpublished results), did not inhibit T cell adhesion to invasin. Thus, these data strongly suggest that VLA-4 is the predominant invasin receptor on human T cells.
VLA-4 Is the Predominant Integrin Inmsin Receptor on
Binding of Resting T Cells to Invasin Requires Metabolic Activity and an Intact Cytoskeleton.
We assessed the ability of various metabolic inhibitors to inhibit the binding of resting T cells to invasin as a first test of whether engagement by invasin generates intracellular signals that might rapidly upregulate VLA integrin activity. The data in Fig. 3 demonstrate that the increased adhesion to invasin observed with PMA-activated T cells can be inhibited to the level of resting T cell binding by the protein kinase C (PKC) inhibitor staurosporin. However, staurosporin did not inhibit resting T cell adhesion to invasin, suggesting that adhesion of resting T cells to invasin is not dependent on PKC activation. Treatment of T cells with the cAMP analogue dibutyryl cAMP, which has been shown to inhibit activation-dependent T cell adhesion to FN and ICAM-1 (4, 7), or the tyrosine kinase inhibitor herbimycin A also did not inhibit the binding of resting T cells to invasin (Fig. 3 and data not shown) . However, treatment of T cells with sodium azide significantly inhibited invasin binding by resting T cells, suggesting that T cell adhesion to invasin requires a metabolically active T cell. Furthermore, the ability of the cytoskeletal disrupting agent cytochalasin B to inhibit the binding of both resting and PMA-activated T cells to invasin is consistent with earlier data implicating the cytoskeleton in integrin-mediated adhesive events (21) . Treatment of T cells with EDTA also abolishes T cell binding to invasin, consistent with the divalent cation requirements of integrin receptors. T cells are activated through the CD3-TCR by the CD3-specific mAb OKT3 immobilized on plastic. In the absence of accessory cells, human T cells fail to proliferate in response to immobilized CD3 mAb alone (9, 19) . However, vigorous T cell proliferation occurs when a VLA integrin ligand, such as FN, laminin, or VCAM-1, is coimmobilized with the CD3 mAb (9, 15, 19, 22) . Fig. 4 shows that as with other VLA integrin ligands, coimmobilization of invasin with the CD3 mAb OKT3 can also result in T cell proliferation. The same VLA4 o~ chain-and VLA/~ chain-specific mAbs that inhibit T cell adhesion to invasin (Fig. 2 ) also inhibit T cell proliferation induced by coimmobilized invasin and CD3 mAb (data not shown).
Invasin Facilitates CD3-raediated T Cell Proliferation
Discussion
We have shown in this study that human CD4 + T cells bind via VLA integrins to the bacterial protein invasin. However, unlike other VLA integrin ligands, there is strong adhesion of resting T cells to invasin with a relatively small increase in the overall strength of adhesion after modes of activation that dramatically increase T cell adhesion to other integrin ligands such as FN, VCAM-1, and laminin. Thus, these findings illustrate an important additional regulatory component to integrin receptors. Other properties common to integrin ligands, such as the ability to facilitate CD3-mediated T cell proliferative responses (Fig. 4) , are also exhibited by invasin.
The exact mechanism by which invasin promotes such vigorous adhesion of resting T calls to invasin currently remains undefined. One possibility is that the high affinity of invasin for its VLA integrin receptors can overcome the low functional activity ofVLA integrins on resting T cdlL This mechanism would suggest that any integrin ligand with suf~dently high atfinity would be able to mediate the adhesion of resting T cells. A second possibility is that binding of resting T cells to invasin results in the generation of a signal that upregnlutes VLA integrin activity. This hypothesis is supported indirectly by: (a) the requirement for a metabolically active T call to observe binding to invasin (Fig. 3) ; and (b) numerous reports of mAbs directed against the VLA-4 ot chain or the VLA/3 chain that can upregnlate adhesion to relevant ligands (17, 18, (23) (24) (25) . We are continuing to investigate the potential of invasin as an integrin regulatory molecule. Nevertheless, our results dearly illustrate that in addition to the already well established role of activation in regnlating T cell integrin function, the nature of the ligand itsdf also plays an important role in regulating adhesion. Thus, integrinmediated adhesion to distinct ligands can be regulated in very different ways. mAb blocking studies indicate that the VLA-4 integrin is the predominant invasin receptor on CD4 + T cells (Fig.  2) . Even though CD4 + T cells express VLA-3, VLA-5, and VLA-6, and these VLA integrins have previously been shown to bind to invasin (12), we were unable to identify any mAbs specific for VLA-3, VLA-5, or VLA-6 that were able to inhibit T cell binding to invasin. This may be due to the higher levels of VLA-4 expressed on CD4 + T cells compared with VLA-3, VLA-5, and VLA-6 (6). However, the contribution of specific VLA integrins to adhesion to a specific ligand does not always correlate with the levd of integrin expression. For example, T cell adhesion to FN is mediated predominantly by VLA-5, even though it is expressed at lower levels on T cells than VLA-4, which also binds FN (6) . There may also be cell type-specific differences in the ligand specificity of individual VLA integrins since VLA-2 has been shown to differentially recognize laminin depending upon the specific type of cell in which VLA-2 is expressed (26) . Thus, it is conceivable that VLA-3, VLA-5, and VLA-6 on human T cells do not function as invasin receptors as they do on other cell types that express these receptors. The inability of the VLA-5-specific mAb BIIG2 to inhibit T cell binding to invasin is consistent with this hypothesis, since this mAb was previously shown to inhibit the binding of K562 cells to invasin (12) .
Although enteropathogenic bacteria such as Yersinia are thought to mainly interact with epithelial and other connective tissue cells, T cell interactions with bacteria may also be relevant to our understanding of bacterial pathogenicity. Our results suggest that invasin allows Yersinia to potentially interact with any human cells that express the appropriate VLA integring even cells that normally express these receptors in a low activity functional state. This strategy allows invasinbearing bacteria to overcome the normal mechanisms that regulate integrin functional activity. The ability of invasin to facilitate CD3-mediated T cell proliferation (Fig. 4) suggests that Yersinia might also be able to modulate the im-mune response in vivo by VLA integrin-mediated interactions with invasin. Our data, coupled with other indirect lines of evidence such as localization of Yersinia to anatomic sites rich in T cells such as Peyer's patches (27) and the isolation of Yersinia-specific T cell clones (28) , suggest that further investigation of the significance of lymphocyte interactions with bacterial pathogens is warranted.
